valu usd unless otherwis note
see hurdl stay sector perform
lower price target
view stand larg pharma cut outlook given
exposur physician-administ revenu make hard argu
defens peer add risk see second
wave/extend distanc pend legaci product spin add
uncertainti given assum capit redeploy remain
sector perform sidelin see stock rang bound
look past strong number move lower due
deviat peer first cut guidanc full-
year revenu ep guid move lower billion
midpoint part foreign exchang absorb
other also reflect mix given higher weight toward physician-
administ drug two-third pharma revenu anim health
share year-to-d versu drg concern may
partial price leav take ep
like base survey link sell-sid buy rate
case cautiou follow guidanc cut illustr
defens least rel peer leav risk
under-perform group peer highlight resili
risk second wave/extend distanc remain risk
pend spin newco/organon time reiter
add execut risk/uncertainti billion remain-co
synergi see updat spin-co exhibit plan lever spin-co
billion use proce next year repurchas share
partial off-set dilut potenti recess risk
keytruda remain big driver concentr set rise
post spin grow competitor data headlin come
see lower risk remain focu
high-level assumpt larg line peer
lot color focus across
group updat guidanc assum major neg impact
fall eventu return normal oper
notabl sever pocket strength includ vaccin anim
expect revers due larg part patient access
challeng lot specif color outlook
focu link emphas
medicaid account small portion busi could matter
unemploy remain elev took first cut updat
model impact earlier month link trim
estim today revenu ep move
billion near midpoint guidanc
price prior trade day market close estimate unless otherwis note
capit market appreci consider institut investor all-america research survey
invest thesi merck keytruda remain
key growth driver busi next sever
year declin busi segment continu
throw steadi cash strateg early-stag
deal augment pipelin diversifi busi longer
term thesi base follow key point
support sector perform rate
see continu strong growth ahead
keytruda still plenti runway loss
exclus loe concern becom urgent issu
seen stock sell three year ahead meaning
loe cliff give merck plenti time
keytruda loe compani growth larg
driven keytruda sever tailwind
maintain momentum
bolt-on deal help diversifi mix augment
pipelin help compani navig keytruda loe
long runway loe limit urgenc near term
larger deal allow concentr bolt-on
strategi though uncertainti given pend ceo
transit also see room potenti portfolio prune
declin busi unit
merck margin expans stori compel
rel uniqu among peer continu oper
leverag busi compani shift primari
care toward specialty/oncology/hospit focu redirect
spend effici segment
potenti catalyst data read focu phase readout
keytruda adjuv tnbc
metastat tnbc pneumococc
vaccin continu busi develop
augment pipelin new ceo announc
close spin women health biosimilar legaci
risk thesi competit risk keytruda
particularli nsclc bmy/azn greater-than-
expect price pressur busi greater
suppli pressur expect gardasil continu
limit growth ahead new manufactur come on-line
bloomberg capit market estim upside/downside/target
base-cas scenario see price target impli
price-to-earnings remainco ep
assum keytruda remain primari growth driver
busi market leader nsclc
continu steadi oper margin expans
compani shift resourc away primari care
modest declin price across portfolio
specif built estim expect continu
capit deploy focus bolt-on deal dividend
growth stock repurchas
upside-cas scenario see price target impli
price-to-earnings remainco ep
better-than-expect growth margin expans larg
driven keytruda
lack meaning competit challeng keytruda
specif built estim expect continu
capit deploy focus bolt-on deal dividend
growth stock repurchas
downsid case scenario see price target
impli price-to-earnings remainco ep
greater competit impact keytruda expect
slower uptak key geographi china
wors price pressur anticip across portfolio
disappoint key pipelin data read
specif built estim expect continu
capit deploy focus bolt-on deal dividend
growth stock repurchas
updat pro forma stand-alone model merck remainco
newco organon
stand-alone basi model ep merck remainco reflect
full separ newco busi made two import assumpt
directli influenc ep assum half billion proce newco
redeploy share repurchas deliv ep support assum merck
share-repurchas program reinstitut ii model million year-
one oper effici add anoth ep without two offset
stand-alone remainco ep would
exhibit updat remainco stand-alone ep assum newco special dividend
remainco pro-forma compound-annual-growth-rate improvementrevenu growth increment net oper efficienciesoper margin oper effici per year beg incom pro-forma margin pro-forma target assum total ebitda margin pro-forma assum total less legaci ladd incom lpre-tax incom incom non-controlling lpro forma net pro-forma ep increment share buybacksremainco pro-forma ep newco div use buyback pro-forma ep newco div use buyback share close share share count case assum newco dividend redeploy share buyback share count newco dividend redeploy share buyback tax-fre receiv special tax-fre dividend newco upon closetax capit structurecom net b/sless special dividend receiv special tax-fre dividend newco upon closeadd dividend use case assum newco dividend redeploy share buyback pro-forma net ebitda equiti equiti pt impli ev/ebitda valuat remainco forecastsimpli equiti equiti merck co inc
newco model ep assum million
increment stand-alone cost dis-synergi biggest differ
forecast merck guidanc pertain newco growth outlook specif model
low-single-digit revenu eros base wherea merck guid low-
single-digit revenu growth result also model flat instead grow margin
er side caution pend detail newco growth initi
meaning swing factor valuat
exhibit updat newco organon stand-alone ep assum million increment
newco pro-forma growth increment stand-alon costsoper margin stand-alon assum year newco revenueoper incom margin pro-forma rang year assum total ebitda forma newco ebitda low-to-mid rang year assum total less newco cost newco debtpre-tax incom incom forma net pro-forma capit structurecommentsnewco pro-forma net newco expect initi net ebitda equiti equiti pt impli ev/ebitda valuat newco forecast roughli compar impli equiti equiti exhibit
merck incom guid billioncost product profit guid gross guid sg flat guid increas investmentoper incom guid opex low single-digit rate decreaseinterest incom expens incom expens guid expenseearn incom tax tax guid earn earn ep guid share share guid billion sharesdividend per yield base price base price targetebitda estimateebitda guid gross guid profit analysi guid guid sg flat guid increas investmentoper share per merck co inc
price target base equal price-to-earnings ev/ebitda remainco estim use
multipl respect get us per share ad per
share contribut newco spin close multipl use reflect
price target framework appli discount histor industri averag
give compani credit high-growth profil off-set portfolio
concentr keytruda impli return price target support sector perform
risk rate price target
risk rate price target includ limit tail valu risk loss
exclus loe concern januvia primarili keytruda busi
develop risk compani continu activ posit long-term
growth portfolio diversif outsid keytruda focus smaller/earlier-stag
asset inher riski pipelin risk work develop acquir
intern develop asset pricing/polit risk broadli applic
sector particularli around pricing/reimburs
merck global biopharmaceut compani base kenilworth nj compani report
two segment anim health segment compris
human health pharmaceut product segment sever differ busi unit
largest oncolog vaccin
